Universiti Putra Malaysia
upm.edu.myTotal trials
140
Active
34
Phase 3
1
Total enrollment
58,994
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Adjunctive Aripiprazole for improving Weight and Metabolic Outcomes in Females | — | — | — | — | — | 1 |
Next readouts
- 2025-03-15
Top conditions
- Type 2 Diabetes Mellitus6
- Mental Health Issue5
- Physical Inactivity5
- Physical Fitness4
- Obesity4
- Metabolic Syndrome3
- Type 2 Diabetes2
- Childhood Obesity2
Frequently asked questions about Universiti Putra Malaysia
- How many clinical trials does Universiti Putra Malaysia have on ClinicalTrials.gov?
- Universiti Putra Malaysia is listed as the lead sponsor on 140 clinical trials in ClinicalTrials.gov, 34 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Universiti Putra Malaysia's trials are in Phase 3?
- 1 of Universiti Putra Malaysia's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Universiti Putra Malaysia focus on?
- Universiti Putra Malaysia's most-studied conditions on ClinicalTrials.gov are Type 2 Diabetes Mellitus, Mental Health Issue, Physical Inactivity, Physical Fitness, Obesity.
- When are Universiti Putra Malaysia's next clinical trial readouts?
- Universiti Putra Malaysia has 1 upcoming primary-completion readout tracked here; the soonest is “Evaluating the Effects of Adjunctive Aripiprazole on Weight and Metabolic Outcomes in Females”, expected around 2025-03-15.